What new treatments for Mantle Cell Lymphoma are being developed in 2026

New and Emerging Treatments for Mantle Cell Lymphoma in 2026

Based on the most current NCCN Guidelines (Version 3.2025), here's what's happening with mantle cell lymphoma (MCL) treatment development:

Recently Approved & Emerging Approaches

1. Zanubrutinib-Based Combinations (Newest)

The most recent advancement highlighted in 2025 guidelines is zanubrutinib combined with obinutuzumab and venetoclax for patients with TP53-mutated MCL. According to NCCN Guidelines, this triple combination represents a significant development for this high-risk group, as TP53 mutations have historically been associated with poor prognosis.

Why this matters: TP53 mutations make cancer cells more aggressive and resistant to standard treatments. This new combination specifically targets this challenging subtype.

2. Covalent BTK Inhibitors (Bruton Tyrosine Kinase Inhibitors)

The NCCN Guidelines emphasize three covalent BTKi options as preferred treatments:

• Ibrutinib (the original BTKi)
• Acalabrutinib (newer, more selective)
• Zanubrutinib (newest generation)

These are being used in multiple combinations with chemotherapy and other targeted drugs.

3. CAR T-Cell Therapy Expansion

According to NCCN Guidelines, CAR T-cell therapies continue to be refined for relapsed/refractory MCL:

• Brexucabtagene autoleucel (ZUMA-2 study showing 3-year follow-up data)
• Lisocabtagene maraleucel (TRANSCEND NHL 001 trial)
• Axicabtagene ciloleucel (ZUMA-5 for indolent lymphomas)

What CAR T means: These are engineered immune cells trained to recognize and attack lymphoma cells. They're particularly important for patients who've failed other treatments.

4. Non-Covalent BTK Inhibitors

Pirtobrutinib represents a new class of BTK inhibitor that works differently than earlier versions. According to NCCN Guidelines, it's being used for patients who've already received covalent BTKi therapy and developed resistance.

5. Bispecific Antibodies

The NCCN Guidelines mention CD3 x CD20 bispecific antibody therapy as an emerging approach, though they note that CD20 positivity should be confirmed with rebiopsy before starting treatment.

What this means: These are antibodies designed to bridge cancer cells and immune cells, bringing them together to fight the lymphoma.

Treatment Approach by Disease Stage

According to NCCN Guidelines, the strategy depends on your specific situation:

For newly diagnosed aggressive MCL:

• Preferred options include TRIANGLE regimen (alternating chemotherapy + BTKi), LyMA regimen, or Nordic regimen
• Aggressive therapy followed by maintenance with BTKi or rituximab

For relapsed/refractory MCL:

• Second-line therapy with covalent BTKi-containing regimens (preferred)
• CAR T-cell therapy if not previously given
• Non-covalent BTKi as alternative
• Clinical trials strongly encouraged

Important Context: TP53 Mutation Testing

The NCCN Guidelines emphasize that TP53 sequencing is now essential at diagnosis. This genetic test determines whether you have a TP53 mutation, which significantly impacts treatment selection. Patients with TP53-mutated MCL are specifically recommended for clinical trials, and the new zanubrutinib/obinutuzumab/venetoclax combination is one of the first standard options for this group.

Questions to Ask Your Oncologist

1. Has my MCL been tested for TP53 mutations? This determines which newer combinations might be most appropriate for me.

2. Am I eligible for any clinical trials testing these newer combinations? Clinical trials often provide access to cutting-edge treatments before they're widely available.

3. If I have relapsed/refractory disease, have we discussed CAR T-cell therapy options? These have shown durable responses in some patients.

4. Which BTKi approach would you recommend for my specific situation—covalent or non-covalent? The choice depends on your prior treatments and disease characteristics.

5. What is the maintenance strategy after my initial treatment? NCCN Guidelines recommend either BTKi or rituximab maintenance depending on your initial therapy.

Key Takeaway

The landscape for MCL treatment is rapidly evolving, with increasing emphasis on personalized approaches based on TP53 status and combination therapies rather than single agents. The integration of targeted therapies (BTKis), immunotherapy (CAR T), and chemotherapy is becoming more sophisticated, offering better outcomes than older single-drug approaches.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines Version 3.2025: Mantle Cell Lymphoma
• Recent clinical trial data referenced in NCCN Guidelines (TRIANGLE, TRANSCEND NHL 001, ZUMA-2, ZUMA-5)